Physician profile
Dixitkumar Modi
NPI 1124238506
$1,682.08
in general payments reported to CMS, 2019-2025
19 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $275 · 2021: $178 · 2022: $199 · 2023: $318 · 2024: $383 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $264.95 | 2020-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $226.10 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $207.36 | 2024-2025 | Voquezna |
| Abbvie INC. | $128.93 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $125.45 | 2019-2024 | Farxiga, Breztri |
| Idorsia Pharmaceuticals US INC | $109.81 | 2023-2024 | Quviviq |
| Novo Nordisk INC | $85.35 | 2019-2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $77.37 | 2019-2022 | |
| Pfizer INC. | $72.21 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $63.26 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $60.90 | 2021 | |
| Merck Sharp & Dohme LLC | $52.64 | 2019-2020 | |
| Exact Sciences Corporation | $46.31 | 2023-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $39.06 | 2021-2023 | Gralise |
| Abbott Laboratories | $37.45 | 2022-2024 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.70 | 2020-2024 | Synjardy, Jardiance |
| Amarin Pharma, INC. | $21.44 | 2019 | |
| Biotronik INC. | $17.41 | 2023 | Biomonitor |
| Astellas Pharma US INC | $15.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dixitkumar Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.